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Objectives We assessed the hypothesis that changes in endothelial vasomotor function in response to optimized therapy
for atherosclerotic coronary artery disease predict future cardiovascular events.
Background Although endothelial vasomotor dysfunction is a predictor of cardiovascular events, it remains unclear whether
reversibility of endothelial dysfunction in response to risk factor reduction provides prognostic information.
Methods This study included 251 patients with newly diagnosed coronary artery disease and an impaired flow-mediated
dilation (FMD) of the brachial artery (FMD 5.5%). Measurement of FMD was repeated after 6 months for indi-
vidualized and optimized therapy to reduce risk factors according to American College of Cardiology/American
Heart Association guidelines. Patients were followed up for 36 months or until 1 of the following events oc-
curred: cardiac death, nonfatal myocardial infarction, recurrent and refractory angina pectoris requiring coronary
revascularization, or ischemic stroke.
Results FMD was persistently impaired (5.5%) in 104 (41%) patients after 6 months of optimized therapy, whereas it
improved (FMD 5.5%) in the remaining 147 (59%) patients. During 36 months of follow-up, events occurred in
27 (26%) patients with persistently impaired FMD and in 15 (10%) patients with improved FMD (p  0.01 by
chi-square test). Multivariate Cox hazards analysis showed that persistent impairment of FMD was an indepen-
dent predictor of events (hazard ratio: 2.9, 95% confidence interval: 1.5 to 6.2, p  0.01). Baseline FMD before
the optimized therapy to reduce risk factor had no significant prognostic information.
Conclusions Persistent impairment of endothelial vasomotor function despite optimized therapy to reduce risk factors has an
adverse impact on outcome in coronary artery disease patients. (J Am Coll Cardiol 2009;53:323–30)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.074(
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endothelial vasomotor dysfunction is an early event identi-
ed in the pathogenesis of atherosclerosis (1–4) and is
ainly caused by loss of endothelium-derived nitric oxide
EDNO) (5–9). Because EDNO has strong antiatherogenic
ffects (5,10), endothelial dysfunction is involved in the
evelopment of atherosclerotic cardiovascular disease
CVD). Moreover, endothelial vasomotor dysfunction is
ecognized as a predictor of adverse cardiovascular outcomes
rom the Department of Internal Medicine II, University of Yamanashi, Faculty of
edicine, Yamanashi, Japan. This study was supported by grants-in-aid for (B)(2)-
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5012222” from the Ministry of Education, Culture, Sports, Science, and Technol-
gy, Health and Labor Sciences Research Grants for Comprehensive Research on
ging and Health (H15-Choju-012), Tokyo, Japan.s
Manuscript received April 10, 2008; revised manuscript received August 6, 2008,
ccepted August 30, 2008.11–14). However, a decrease in EDNO and endothelial
asomotor dysfunction is reversible after a reduction in
therosclerotic risk factor burden by pharmacological inter-
entions and life-style modifications (15–20). Because a
eduction in risk factors improves endothelial vasomotor
unction, a single assessment of endothelial vasomotor
See page 331
unction may not necessarily reflect later EDNO activity,
nd endothelial function measured at a single time point
ay not reflect long-term progression of atherosclerotic
iseases. Most previous studies (12–14) that used endothe-
ial function to predict future cardiovascular events assessed
ndothelial function at only a single time point; only a few
tudies evaluated the prognosis based on serial measure-
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(11,21). Modena et al. (11) first
tested the prognostic role of re-
versing endothelial vasomotor
dysfunction in post-menopausal
women with mild-to-moderate
hypertension. They enrolled pa-
tients with a low prevalence of
other risk factors and no previ-
ous cardiovascular events, and
showed that patients with im-
proved flow-dependent dilation
of the brachial artery (flow-
mediated dilation [FMD]) after
antihypertensive therapy had
fewer events during follow-up.
Thus, recovery from endothelial
asomotor dysfunction was associated with reduced cardio-
ascular events in their hypertensive patients. However, that
eport (11) did not assess the changes in other confounding
ariables such as diabetes mellitus that might have influ-
nced outcome. Moreover, it remains unknown whether the
ssociation between reversible endothelial function and
avorable outcome is also true in patients with coronary
rtery disease (CAD) and advanced atherosclerotic burden.
hus, this study examined whether changes in endothelial
asomotor function in response to optimized therapy for
therosclerotic burden provide prognostic information on
uture cardiovascular events in patients with CAD.
ethods
tudy patients. This study enrolled 251 patients from
mong 302 consecutive patients with newly diagnosed
AD who were admitted to Yamanashi University Hospital
or coronary angiography from April 2002 to March 2004.
he inclusion criteria included an impaired FMD (5.5%)
t enrollment (first FMD) and a second test of FMD
epeated 6 months after the first FMD test at the enroll-
ent. All patients had angiographic documentation of
rganic stenosis of70% of at least 1 major coronary artery.
atients were excluded based on the presence of any of the
ollowing criteria: 1) acute coronary syndrome, stroke,
ardiogenic shock, pulmonary edema, major surgery,
rauma, or serious infectious disease within 4 weeks prior to
nrollment and during 6 months between first and second
MD test; 2) New York Heart Association functional
lassification III; 3) left main trunk disease; 4) left
entricular ejection fraction on echocardiography 30%;
) neoplasm, chronic hepatic or inflammatory diseases;
) chronic renal failure (serum creatinine levels 2.0
g/dl); and 7) other serious systemic diseases. Among
he 302 eligible patients with CAD, 51 patients were
xcluded because of FMD 5.5% in 38 patients, a CVD
vent between first and second FMD test in 3 patients, and
Abbreviations
and Acronyms
CAD  coronary artery
disease
CVD  cardiovascular
disease
EDNO  endothelium-
derived nitric oxide
FMD  flow-mediated
dilation
Hb  hemoglobin
LDL-C  low-density
lipoprotein cholesterol
ROC  receiver-operator
characteristiche other exclusion criteria in 10 patients. This study also cncluded 100 control subjects with angiographically normal
oronary arteries and normal ventriculography. These con-
rol subjects were selected to match the age and sex of the
atients with CAD. The FMD measurements were once
erformed at the enrollment of these control subjects, and
heir FMD values were compared with those of the CAD
atients. The characteristics of the study patients and the
ontrol subjects are shown in Table 1. Written informed
onsent was obtained from all patients and control subjects
efore the study. This study was in agreement with the
uidelines approved by the ethics committee at our
nstitution.
tudy protocol. Measurement of FMD in the brachial
rtery was performed in the morning after an overnight fast
n the same manner within 3 days (first FMD) before the
oronary angiography and 6 months (second FMD) after
he first FMD test in all study patients with CAD. All
asodilators were withdrawn 48 h before the FMD mea-
urements. After the first FMD measurement, all patients
ad individualized, optimized therapies including medica-
ions and life-style changes to reduce risk factors for CAD
ccording to the AHA/ACC guidelines (22,23). The target
or low-density lipoprotein cholesterol (LDL-C)-lowering
herapy was100 mg/dl (2.6 mmol/l), hypertension control
as 140/90 mm Hg (or 130/80 mm Hg if diabetes
resent), and hemoglobin (Hb)A1C 7.0% for diabetes
ontrol. All patients were advised to maintain or reduce
aist circumference to 85 cm in men and 90 cm in
omen through an appropriate balance of physical activity
walking 30 min/day) and caloric intake according to the
xamination Committee of Criteria for Obesity Disease in
apan (24). All patients were followed up in the hospital or
ith a clinic visit every month and encouraged to adhere to
he life-style changes and diet recommendations. Levels of
erum lipids, HbA1C, and C-reactive protein were assayed,
s described previously (25).
ollow-up study. After the second FMD test, all of the
51 patients with CAD were prospectively followed up
very month in the hospital or with a clinic visit for up to 36
onths or until the occurrence of 1 of the following clinical
VD events: cardiac death, nonfatal myocardial infarction,
ecurrent or refractory angina pectoris requiring coronary
evascularization by percutaneous coronary intervention or
oronary artery bypass surgery, or ischemic stroke. The time
o the first CVD event was evaluated prospectively. Diag-
osis of myocardial infarction was made by chest pain,
ppearance of a new Q-wave in the electrocardiogram, and
levation of plasma creatine kinase to more than twice the
pper limit of normal. The cause of death was determined
rom hospital records. All end point data were checked for
ccuracy, consistency, and completeness of follow-up by the
nvestigators (J.O., K.S.) without knowledge of the patients’
aseline characteristics. The same medications prescribed
uring the 6 months between the first and second FMD
ests and the recommended diet and life-style changes were
ontinued in each patient throughout the follow-up period.
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January 27, 2009:323–30 Persistent Endothelial Dysfunction and Prognosiseasurements of FMD in the brachial artery. Vasodila-
or responses in the brachial arteries were measured by use
f B-mode ultrasound images with a 7.5-MHz linear array
ransducer (HP-5500, Phillips Corp., Tokyo, Japan) as
escribed in our previous studies (17,25). Briefly, optimal
rachial artery images were obtained between 1 and 5 cm
bove the antecubital crease. This location was marked, and
ll subsequent images were obtained at the same location.
he exact distance of the measured point on the skin surface
rom the antecubital crease was recorded in each subject to
nsure that the same segment of the brachial artery was
easured at each time point during follow-up. The re-
ponses of the vessel diameter and blood flow to reactive
yperemia and nitroglycerin were expressed as percentage
ncreases in diameter and blood flow from the baseline
alue, respectively. In our studies, the repeated measure-
ent of baseline arterial diameter had an interobserver
ariability of 0.04  0.01 mm, and an intraobserver vari-
bility of 0.02  0.01 mm. When these studies were
erformed at the same time on 2 separate days in 20 control
ubjects, the difference in arterial diameter during reactive
yperemia between the 2 days in each subject was 0.05 
.01 mm, yielding a mean difference of 1.1  1.0% of
MD. Impairment of FMD was pre-defined as 5.5%
mean minus 1 SD of FMD in 100 healthy normal subjects
n our hospital) before the start of the recruitment of CAD
atients into this study.
tatistical analysis. Data were expressed as the mean 
Comparisons of Baseline Clinical Characteristic
Table 1 Comparisons of Baseline Clinical Ch
Characteristic
Patie
Persistentl
(n
Age, yrs 68
Male sex, %
Hypertension, %
Patients with BP 140/90 mm Hg, %
Patients with LDL-C 100 mg/dl, %
Diabetes mellitus, %
Patients with HbA1c 7.0%, %
Current smoker, %
Family history of CAD, %
Multivessel CAD, %
Percutaneous coronary intervention, %†
Body mass index, kg/m2 24
Waist circumference, cm 86
Systolic BP, mm Hg 137
LDL-C, mg/dl 130
HDL-C, mg/dl 48
HbA1c, % 6.1
CRP, mg/l 4.3
Data are expressed as mean  SD or percentage of the patients.
persistently impaired flow-mediated dilation (FMD) of the brachial arte
an antihypertensive medication; diabetes mellitus is defined accordin
medication; smoking is defined as 10 cigarettes per day for 10 ye
performed at screening.
BP  blood pressure; CAD  coronary artery disease; CRP  C-reac
LDL-C  low-density lipoprotein cholesterol.D or a percentage. The frequencies between 2 groups of Fatients and the 2 mean values were compared using the
hi-square test and Student paired or unpaired t test,
espectively. For comparisons of the mean values 3
roups, 1-way analysis of variance followed by a Scheffe test
or post-hoc comparisons was employed. The mean value of
ascular variables related to FMD before and during treat-
ent was compared between the 2 groups using 2-way
nalysis of variance for repeated measures followed by
ost-hoc testing with a Scheffe test. Kaplan-Meier analysis
f event-free survival during follow-up was performed with
atients with CAD stratified on the basis of change in
MD. The association of FMD with future events was
ssessed by Cox proportional hazards analysis. The data
ere analyzed initially using a univariate model with covari-
tes, including FMD and other potential confounders that
ad a statistically significant difference between patients
ith and without events. Multivariate Cox proportional
azards analysis was then applied using FMD and the
ovariates that were significantly associated with events in
he univariate Cox proportional hazards analysis. Cox pro-
ortional hazards analysis included the confounders that
ad proportionalities, evaluated by Schoenfeld residuals test.
n this multivariate model, interaction analysis between
ovariates on the outcome was performed using the likeli-
ood test. On the basis of our preliminary observations, we
roposed that the composite end point would occur in
30% of patients with persistently impaired FMD during
6 months of follow-up and in 10% of those with improved
he First FMD Test
teristics at the First FMD Test
ith
ired FMD
)
Patients With
Improved FMD
(n  147)
Control Subjects
(n  100)
66 10 64 11
61 61
65 63
41 38
79 73
34* 24
16* 10
40 31
21* 12
57 —
95 —
24 2.8 23 3.3
85 8 85 7
134 23 133 16
128 35 126 32
46 11 50 14
* 6.2 1.5* 5.5 0.9
* 4.1 8.1* 2.5 4.7
was no significant difference in parameters between patients with
mproved FMD. Hypertension is defined as140/90 mm Hg or taking
e American Diabetes Association report or as taking an antidiabetic
 0.05 versus control subjects. †Percutaneous coronary intervention
tein; Hb  hemoglobin; HDL-C  high-density lipoprotein cholesterol;s at t
arac
nts W
y Impa
 104
 10
54
73
36
81
43*
21*
30
27*
58
94
 3.4
 11
 24
 36
 13
 1.3
 8.3
There
ry and i
g to th
ars. *pMD. Thus, it was estimated that 72 patients would be
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Persistent Endothelial Dysfunction and Prognosis January 27, 2009:323–30eeded in each group (n  144, total) to detect a significant
ifference in events between the 2 groups with a 2-tailed 
f 0.05 and a power of 0.80 (  0.20). A p value of 0.05
as considered statistically significant. Analyses were per-
ormed with StatView 5.0 (SAS Institute, Cary, North
arolina), and STATA version 10.0 (Stata Corp, College
tation, Texas).
esults
MD measurement. At the second FMD test, 104 pa-
ients had persistently impaired FMD (5.5%), whereas the
emaining 147 patients had significantly improved FMD
5.5%) (Fig. 1, Table 2). The baseline FMD at the first
est was comparable between patients with persistently
mpaired FMD and those with improved FMD (Fig. 1,
able 2). Baseline brachial arterial diameter, baseline bra-
hial blood flow, an increase in brachial blood flow during
Figure 1 FMD Comparison Between
First and Second Test in CAD Patients
A comparison between the first and second test of flow-mediated dilation
(FMD) of the brachial artery in patients with coronary artery disease (CAD).
NS  not significant.
rachial Artery Diameter and Blood Flow
Table 2 Brachial Artery Diameter and Blood Flow
Patients With
Persistently Impaired F
First Test Seco
Arterial diameter at rest, mm 4.1 0.8 4.0
Arterial blood flow at rest, ml/min 201 22 226
Increase in arterial blood flow, % 208 18 212
Increase in diameter after nitroglycerin, % 18 5.4 19
FMD, % 3.0 1.5* 3.4ata are expressed as mean  SD. *p  0.01 versus control subjects. †p  0.01 versus first test in pateactive hyperemia, and the dilator response to nitroglycerin
ere not significantly different between the 2 groups at
ither the first or the second test (Table 2). These param-
ters related to vascular vasomotor responses, except for
MD, were similar between patients with CAD and con-
rol subjects (Table 2). In receiver-operator characteristic
ROC) analysis, an optimal cutoff point for FMD in
iscriminating the CAD patients from the control subjects
as 5.2% (sensitivity 87%, specificity 87%), which was
ocated close to 5.5% (sensitivity 89%, specificity 78%), the
re-determined cutoff point for impaired FMD in the
resent study.
omparison of clinical variables at first and second FMD
est between CAD patients with persistently impaired
MD and those with improved FMD. Profiles of athero-
clerotic risk factors at the first and second FMD tests were
omparable between the 2 groups (Tables 1 and 3). Profiles
f atherosclerotic risk factors were equally improved at the
econd FMD test from their baseline values at the first
MD test, and the target achievement rates for blood
ressure control, LDL-C levels, and HbA1c levels at the
econd FMD test were comparable between the 2 groups
Table 3). In addition, the frequencies of cardiovascular
edications used at the first and second FMD tests, dosage
hanges, or the addition of new medications immediately
fter the first FMD test, and the percutaneous coronary
ntervention at entry were comparable between the 2 groups
Tables 1 and 4).
rognostic value of FMD in CAD patients. All of the
51 patients completed the follow-up study (from 2 to 36
onths, mean 31  4 months). Patients with persistently
mpaired FMD had 27 (26%) cardiovascular events (1
ardiac death, 4 nonfatal myocardial infarctions, 15 recur-
ent angina pectoris with coronary revascularization, and 7
trokes) during the follow-up period, whereas patients with
mproved FMD had 15 (10%) events (2 nonfatal myocardial
nfarctions, 10 recurrent angina pectoris with coronary
evascularization, and 3 strokes; p  0.01). Kaplan-Meier
nalysis demonstrated that a persistently impaired FMD
esulted in significantly lower survival without an event than
n improved FMD (p  0.01 by log-rank test) (Fig. 2).
mong FMD and the clinical variables listed in Table 1 at
ither first or second FMD test, persistently impaired
Patients With
Improved FMD
st First Test Second Test Control Subjects
4.0 0.7 4.1 0.8 4.1 0.7
203 23 218 28 196 18
221 20 210 22 210 20
19 5.9 20 6.1 21 6.3
* 3.0 1.0* 7.7 1.3† 7.6 2.0MD
nd Te
 0.9
 27
 16
 7.2
 1.3ients with improved flow-mediated dilation (FMD).
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January 27, 2009:323–30 Persistent Endothelial Dysfunction and PrognosisMD, diabetes mellitus, multivessel CAD, and family
istory of CAD were significantly more frequent in patients
ith than without an event. Furthermore, levels of HbA1c at
he second test were higher in patients with than without an
vent (data not shown). The baseline FMD at the first test
as comparable between patients with and without an event
2.9  1.4% vs. 3.0  1.3%, respectively, p  0.63). In a
nivariate Cox proportional hazards model, persistently
mpaired FMD, diabetes mellitus, multivessel CAD, and
igher HbA1c levels were significant predictors of events
mong the variables that had a significant difference be-
ween patients with and without events (Table 5). A
ultivariate Cox proportional hazards model demonstrated
hat persistently impaired FMD remained a significant
ndependent predictor of future events (Table 5). The
aseline FMD at the first test was not a significant predictor
f a CVD event during the follow-up period in either the
nivariate or multivariate Cox proportional hazards model
Table 5). HbA1c was excluded from the covariates in the
ultivariate Cox proportional hazards analysis because of a
ignificant interaction between diabetes mellitus and HbA1c
evels (p value for interaction 0.001). There was no
ignificant interaction between the other covariates includ-
ng persistently impaired FMD, diabetes mellitus, multives-
el CAD, and baseline FMD at first test (p value for
Comparison of the Clinical Characteristics at thand the Percen Change in Risk S atus From
Table 3 Comparison of the Clinical Characteand the Percent Change in Risk Sta
Risk status at the second FMD test
Systolic BP, mm Hg
Patients with BP 140/90 mm Hg, %
LDL-C, mg/dl
Patients with LDL-C 100 mg/dl, %
HbA1c, %
Patients with HbA1c 7.0%, %
Current smoker, %
HDL-C, mg/dl
Body mass index, kg/m2
CRP, mg/l
Percent change in risk status from the
first to the second FMD test
Systolic BP, %
Patients with BP 140/90 mm Hg, %
LDL-C, %
Patients with LDL-C 100 mg/dl, %
HbA1c, %
Patients with HbA1c 7.0%, %
Current smoker, %
HDL-C, %
Body mass index, kg/m2, %
CRP, %
Data are expressed as mean  SD or percentage of patients. There w
impaired FMD and improved FMD.
Abbreviations as in Table 1.nteraction 0.1 in all). iiscussion
he present study showed that persistent impairment of
ndothelial vasomotor function despite therapies to reduce
therosclerotic risk factors was an independent predictor of
uture cardiovascular events in CAD patients. In contrast,
he baseline FMD before therapies to reduce risk factors did
ot provide significant prognostic information in CAD
atients in the present study. Thus, serial measurements of
MD may be useful for risk stratification in CAD patients.
atients with persistently impaired FMD may need more
ntensive therapy or risk factor modification to reduce future
ardiovascular events. There may be several reasons for the
egative predictive value of the baseline FMD (the first
MD) in the present study. The selection of patients with
AD, who had an impaired FMD at baseline, may partly
ccount for the negative predictive value of baseline FMD in
his cohort of CAD patients.
Endothelial vasomotor function reflects the atherosclerotic
isk burden at the same time of its measurement (1–4,6–8).
owever, endothelial function is changed by modification of
therosclerotic risk burden (15–20). To date, most patients
ith CAD have optimized therapy for reduction of atheroscle-
otic risk factors according to guidelines and evidence estab-
ished from many clinical trials. The antiatherosclerotic treat-
ent suppresses the atherosclerotic burden in parallel with an
ond FMD Testt to the Second FMD Test
s at the Second FMD Test
rom the First to the Second FMD Test
istently Impaired FMD
(n  104)
Improved FMD
(n  147)
127 19 129 20
24 28
102 33 100 30
45 44
6.0 1.1 5.8 0.9
12 9
11 12
51 14 50 13
23 2.3 23 2.8
1.2 2.0 1.2 1.0
4.7 15 4.7 16
32 32
17.7 29 18.1 27
36 35
2.2 10 2.3 11
45 46
65 71
4.6 18 4.9 17
4.2 15 4.3 16
28 63 30 68
gnificant difference in parameters between patients with persistentlye SecFirs
ristic
tus F
Pers
as no simprovement of endothelial function (15,16). Thus, the pre-
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Persistent Endothelial Dysfunction and Prognosis January 27, 2009:323–30ictive value of the endothelial vasomotor function for future
ardiovascular events may be considerably influenced by the
ntiatherosclerotic treatment initiated after the measurement
f the endothelial function. From this point of view, all of the
resent patients consisted of the newly diagnosed CAD pa-
ients, and most of them did not have full medications against
therosclerotic CVD at baseline FMD measurement (first
MD test). However, the improvement of risk factor profiles
fter the 6 months of optimized antiatherosclerotic therapy was
omparison of Medication Usage
Table 4 Comparison of Medication Usage
Persistently
Impaired FMD
(n  104)
Improved FMD
(n  147)
Medications at the first FMD test, %
Statin 14 10
ACE-I/ARB 6 10
Calcium-channel blocker 21 22
Beta-blocker 5 5
Aspirin 50 42
Ticlopidine* 29 30
Sulfonylurea 7 10
Insulin 5 2
Medications increased or newly added
after the first FMD test, %
Statin 52 53
ACE-I/ARB 59 55
Calcium-channel blocker 34 36
Beta-blocker 19 20
Aspirin 50 58
Ticlopidine* 68 66
Sulfonylurea 1 1
Insulin 2 1
Medications at the second FMD test, %
Statin 61 60
ACE-I/ARB 62 60
Calcium-channel blocker 51 52
Beta-blocker 22 20
Aspirin 100 100
Ticlopidine* 92 90
Sulfonylurea 7 10
Insulin 6 3
here was no significant difference in parameters between patients with persistently impaired
ow-mediated dilation (FMD) and improved FMD. *Clopidogrel was not available until May 2006 in
apan.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker.
Univariate and Multivariate Cox ProportionalHazards An lyses of Risk Factors f r Cardiovasc
Table 5 Univariate and Multivariate Cox ProHazards Analyses of Risk Factors fo
Univaria
HR 95% CI
Persistently impaired FMD 3.1 1.5–6.2
Diabetes mellitus* 2.3 1.2–4.5
Multivessel CAD 2.1 1.0–4.3
HbA1c at second test* 1.5 1.1–4.7
Family history of CAD 2.0 0.9–4.1
Baseline FMD at first test 1.1 0.8–1.4*HbA1c was excluded from the covariates in themultivariate Cox proportional haza
CI  confidence interval; HR  hazard ratio; other abbreviations as in Tablssociated with normalization of FMD at the second FMD
est to that observed in control subjects in patients with
mproved FMD. In these patients, the baseline FMD hardly
eflected the atherosclerotic risk burden after the antiathero-
clerotic treatment. This may be another reason for the
egative predictive value of the baseline FMD. Therefore, it is
easonable that a change in endothelial function in response to
ntiatherosclerotic treatment may be a better predictor of
uture cardiovascular events than the measurement of pre-
reatment endothelial function at a single time point.
Risk factor modification was not optimal in some of the
atients in the present study owing to the so-called treat-
ent gap, including suboptimal dosages of drugs and poor
atient compliance. The failure of attainment of the target
DL-C levels in some of the present patients may be partly
aused by relatively suboptimal dosages of statin due to
dvanced age or very high LDL-C levels at the baseline.
owever, it was unlikely that insufficient risk factor reduc-
ion was the only cause for lack of improvement of endo-
Figure 2 Kaplan-Meier Curves of Event-Free Survival
Kaplan-Meier curves of event-free survival on the basis of change in flow-
mediated dilation (FMD) in response to risk factor reduction during the
follow-up period (mean, 31  4 months) in 251 patients with coronary artery
disease (104 patients had persistently impaired FMD, and 147 patients had
improved FMD). The cutoff value (5.5%) for the impairment of FMD was pre-
determined from the mean minus 1 SD of FMD in 100 normal subjects in our
hospital.
Events
onal
rdiovascular Events
Multivariate
p Value HR 95% CI p Value
0.001 2.9 1.5–6.2 0.002
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ttainment rates of risk factors to the target levels were
imilar between patients with persistent impairment FMD
nd those with improved FMD. Undetermined risk factors
r genetic predisposition may play a role in the failure of
ndothelial function to improve in response to therapy (26,27).
It is known that the risk factor reduction to target levels
fter optimized therapy does not necessarily prevent future
ardiovascular events in all CAD patients. Endothelial
unctional status is not determined solely by the individual
isk factor burden but, rather, may be regarded as an
ntegrated index of all atherogenic and atheroprotective
actors present in an individual patient, including known as
ell as unknown variables. Thus, measurement of endothe-
ial vasomotor function, a comprehensive analysis of athero-
clerotic burden, may provide a better predictive value of
uture cardiovascular events than the analysis of each of the
raditional risk factors alone.
tudy limitations. This study is preliminary and consider-
bly limited by the small number of study patients, and that
educes the power of the statistical analyses. A large pro-
pective trial is required to understand the precise role of
ersistent endothelial vasomotor dysfunction in the patho-
enesis and progression of atherosclerotic disease. Also,
tandardized and reproducible techniques for FMD mea-
urement need to become available for multicenter trials.
he cutoff point of 5.5% for impaired FMD in the present
tudy may not be necessarily applied to other FMD studies
ecause the FMD value is considerably influenced by
echnical issues, age, sex, brachial arterial diameter, and so
n (2–4). However, the cutoff point of 5.5% for impaired
MD seems to be reasonable in the present study because
his pre-defined cutoff point was close to an optimal cutoff
oint of 5.2%, as determined by ROC analysis, for baseline
MD in discriminating CAD patients from control subjects
ncluded in the present study.
onclusions
ersistent endothelial vasomotor dysfunction in the brachial
rtery may be related to future cardiovascular events despite
ell-established antiatherosclerotic therapy for CAD pa-
ients. Periodic measurement of FMDmay be useful for risk
tratification of CAD patients.
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